Advances in Alzheimer's Disease Treatment: From Anti-Amyloid Antibodies to Multi-Target Strategies
核心洞察
Alzheimer's disease (搜索) affects 55 million people worldwide, with prevalence reaching 20–30% in those aged 85 and older, and dementia cases are projected to hit 150 million by 2050.
The FDA has granted traditional approval to lecanemab (2023) and donanemab (2024) for early symptomatic AD, while aducanumab received accelerated approval in 2021 amid controversy.
As of January 2025, 182 clinical trials are evaluating 138 investigational agents, with 31 candidates in Phase 3 trials targeting amyloid, tau (搜索), neuroinflammation, and other pathways.
The therapeutic landscape for Alzheimer's disease (搜索) (AD) is undergoing a profound transformation, driven by the first disease-modifying therapies to reach the market and an expanding pipeline of investigational agents targeting multiple pathological pathways. As of January 2025, a total of 182 clinical trials evaluating 138 investigational agents are underway, reflecting the urgency of addressing a disease that currently affects 55 million people worldwide—a figure expected to reach 150 million by 2050.
Alzheimer's disease (搜索), the most common cause of dementia responsible for 60–80% of cases, is characterized by progressive memory loss, cognitive decline, and loss of functional abilities. Among people over 65, prevalence ranges from 4% to 7%, increasing to 20–30% in those aged 85 and older. The disease imposes a significant emotional and economic burden on families, carers, and healthcare systems globally.
The Amyloid Hypothesis Gains Clinical Validation
The most significant recent advances have come from anti-amyloid immunotherapies. After decades of clinical failures, several monoclonal antibodies targeting amyloid-beta (搜索) (Aβ) have achieved regulatory milestones. Lecanemab (BAN2401), a humanized monoclonal antibody that selectively binds to soluble Aβ protofibrils, received traditional FDA approval in July 2023 for treating mild cognitive impairment (MCI) and mild dementia associated with Alzheimer's disease (搜索). The Phase III Clarity study demonstrated a statistically significant reduction in the rate of decline across global, cognitive, and functional measures in early AD, along with a marked decrease in brain amyloid levels.
Donanemab, an IgG1 monoclonal antibody targeting a modified, insoluble form of Aβ predominantly found within amyloid plaques, received its first regulatory approval in the United States on July 2, 2024, for patients with early symptomatic Alzheimer's disease (搜索), following demonstration of slowed disease progression in a Phase III trial.
Aducanumab (BIIB037), a human IgG1 monoclonal antibody, was the first new treatment authorized for AD since 2003 when the FDA granted accelerated approval in June 2021. However, its path has been controversial. While the EMERGE Phase III study achieved statistical significance on its primary endpoint, the parallel ENGAGE trial did not. The European Medicines Agency (EMA) withdrew its marketing authorization in April 2022, and development and marketing of the drug have since been halted.
Earlier anti-amyloid antibodies—including bapineuzumab, solanezumab, crenezumab, and gantenerumab—failed to demonstrate clinical efficacy in Phase III trials, though gantenerumab continues to be evaluated in ongoing studies expected to run through 2026.
Beyond Amyloid: The Tau (搜索)-Targeting Frontier
Neuropathological and imaging studies have highlighted a stronger association between tau (搜索) pathology and neurodegeneration and cognitive decline in AD, leading to increased emphasis on tau-targeted treatments. Anti-tau strategies include phosphatase modifiers, kinase inhibitors, inhibitors of tau aggregation, microtubule stabilizers, and tau immunotherapy.
In passive immunotherapy, bepranemab (UCB0107) has shown potential, with a trial demonstrating biological reduction in tau (搜索) accumulation accompanied by a significant, moderate improvement in cognition, even though primary endpoints were not met in the overall study population. E2814 (etalanetug), a humanized IgG1 antibody with high affinity for the microtubule-binding region of tau, is currently under investigation in a Phase II/III trial for Dominantly Inherited Alzheimer's Disease (搜索) (DIAD) and in combination with lecanemab for early sporadic AD.
However, several tau (搜索)-targeting antibodies have been discontinued due to lack of efficacy, including gosuranemab (BIIB092), tilavonemab (ABBV-8E12), and zagotenemab. Semorinemab showed a modest beneficial cognitive effect in one Phase II study but did not improve functional or overall outcomes.
On the active immunotherapy front, AADvac1, the first anti-tau (搜索) vaccine tested in clinical trials, demonstrated positive immunogenicity in 98.2% of patients in its Phase II trial, with statistically significant changes in blood and cerebrospinal fluid biomarkers indicating slowed tau pathology progression. These results support transition to Phase III evaluation.
Antisense oligonucleotides represent another emerging approach. BIIB080 (MAPTRx/ISIS 814907), a tau (搜索)-targeting ASO designed to selectively reduce MAPT messenger RNA and lower tau protein production, has shown reductions in cerebrospinal fluid tau levels and decreased tau PET signal in clinical trials, with Phase II results awaited.
Multi-Target Strategies and the Expanding Pipeline
Given the complex multifactorial pathophysiology of AD, multi-target drug approaches have gained attention. Blarcamesine (ANAVEX 2-73), a sigma-1 receptor agonist with multi-target activity, has demonstrated potential neuroprotective effects through restoration of cellular homeostasis, modulation of mitochondrial function, reduction of oxidative stress, and attenuation of amyloid-β and tau (搜索)-related pathology. A Phase IIB/III trial indicated that blarcamesine could offer a new treatment for early-stage AD, complementing anti-beta-amyloid drugs or serving as a substitute.
ALZ-801, a prodrug of tramiprosate, has shown clinically meaningful cognitive benefits in a 78-week Phase III trial involving APOE ε4/ε4 homozygous individuals, with improvements also associated with daily functioning. The treatment exhibited a favorable safety profile and good long-term tolerability.
Of the 138 investigational agents in clinical trials as of January 2025, 31 drug candidates are being assessed in 48 Phase III trials, 75 candidates in 86 Phase II trials, and 45 candidates in 48 Phase I trials. The pipeline targets include neurotransmitter receptors (32 drugs), Aβ-related pathophysiology (25 candidates), neuroinflammation and immune processes (24 drugs), tau (搜索)-related processes (15 agents), and synaptic plasticity for neuroprotection (9 candidates), among others.
Drug Repurposing: A Parallel Strategy
Drug repurposing has emerged as a significant component of AD drug development. In the 2025 pipeline, 46 repurposed agents are present, corresponding to 33% of all compounds in clinical trials. These agents constitute 39% of Phase III candidates and 41% of Phase II candidates. Notable examples include metformin (Phase III), escitalopram (Phase III), levetiracetam (Phase III), and montelukast (Phase II). Many repurposed agents are approved for indications such as cancer, cardiovascular diseases, diabetes, and neurological disorders.
The Secretase Inhibitor Experience
The development of β- and γ-secretase inhibitors has been marked by repeated failures. Small molecule BACE-1 inhibitors including elenbecestat, atabecestat, umibecestat, verubecestat, and lanabecestat showed significant efficacy in reducing Aβ production but Phase II/III studies could not be continued due to ineffectiveness in slowing cognitive impairment and adverse events such as weight loss, hair discoloration, psychiatric problems, and brain atrophy. Verubecestat and lanabecestat were even associated with worsening of cognitive outcomes. The failure of clinical trials has been attributed to incomplete understanding of BACE1 biology and physiology, limited insight into AD etiology, and reliance on clinical endpoints without validated biomarker-based outcomes.
Biomarkers: The Cornerstone of Modern AD Drug Development
The integration of biomarkers has become central to the approval process of new disease-targeted therapeutics. Among 132 disease-targeting therapy trials, 76 required a biomarker for participant eligibility, and approximately 84% incorporated fluid, imaging, and/or digital biomarkers. Cerebrospinal fluid biomarkers—including Aβ42, total tau (搜索), and phosphorylated tau (particularly p-tau181)—remain the gold standard, while blood-based biomarkers such as the Aβ42/Aβ40 ratio and phosphorylated tau variants (p-tau181, p-tau217, p-tau231) offer a practical, minimally invasive alternative. The inclusion of biomarkers strengthens trial methodology by ensuring appropriate patient selection, confirming target engagement, and enabling objective assessment of therapeutic outcomes.
Looking Forward
The Alzheimer's disease (搜索) therapeutics market reflects this intense research activity, with the global market expected to grow from US$5.36 billion in 2024 to US$31.04 billion by 2034, at a CAGR of 19.2%. While significant challenges remain—including the mixed results of anti-amyloid therapies, the complexity of tau (搜索)-targeted approaches, and the need for validated biomarkers—the convergence of disease-modifying approvals, an expanding multi-target pipeline, and advances in precision medicine signal a new era in the treatment of Alzheimer's disease.